Arjo AB (publ) (FRA:A39)
Germany · Delayed Price · Currency is EUR | Market Cap | 674.17M -19.9% |
| Revenue (ttm) | 985.84M -3.1% |
| Net Income | 34.68M -10.7% |
| EPS | 0.13 -10.7% |
| Shares Out | n/a |
| PE Ratio | 19.44 |
| Forward PE | 12.32 |
| Dividend | 0.09 (3.79%) |
| Ex-Dividend Date | Apr 23, 2026 |
| Volume | n/a |
| Open | 2.424 |
| Previous Close | 2.428 |
| Day's Range | 2.424 - 2.424 |
| 52-Week Range | 2.110 - 3.236 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 14, 2026 |
About Arjo AB
Arjo AB (publ) develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia, Latin America, Africa, and the Pacific. It offers products and solutions for patient handling, hygiene, disinfection, medical beds, pressure injury prevention, diagnostics, hygiene, prevention of pressure injuries and blood clots, and leg ulcer treatment and prevention, as well as for obstetric and cardiac diagnostics. The company also provides dementia care, bariatric room solutions, prone positioning... [Read more]
Financial Performance
In 2025, Arjo AB's revenue was 11.00 billion, a decrease of -2.59% compared to the previous year's 11.29 billion. Earnings were 334.00 million, a decrease of -32.93%.
Financial numbers in SEK Financial StatementsNews
Arjo AB Earnings Call Transcript: Q2 2026
Solid organic growth of 4.7% was achieved, led by global sales, but margin pressure persisted due to higher transportation and material costs. Profitability and cash flow improved, with strong demand expected to continue and strategic updates to be detailed at the upcoming Capital Markets Day.
Arjo AB Quarterly report: Q2 2026
Arjo AB has published its Q2 2026 quarterly earnings report on July 14, 2026.
Arjo AB Slides: Q2 2026
Arjo AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 14, 2026.
Arjo Earnings Up In Q2; Maintains FY26 Sales Growth Outlook
(RTTNews) - Arjo AB (ARJO-B.ST, ARRJF), a Swedish medical technology company, on Tuesday reported higher net income in the second quarter of 2026 compared with the previous year due to high demand for...
Arjo AB Earnings Call Transcript: Q1 2026
Stable Q1 with 3.8% organic growth, strong U.S. and rest of world sales, and improved cash flow. Margins slightly down due to tariffs and FX, but EBIT margin up on lower restructuring costs. Strategy update expected H2 2026.
Arjo AB Quarterly report: Q1 2026
Arjo AB has published its Q1 2026 quarterly earnings report on April 22, 2026.
Arjo AB Slides: Q1 2026
Arjo AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 22, 2026.
Arjo AB Earnings Call Transcript: Q4 2025
Q4 saw stable demand but lower margins due to currency, tariffs, and mix effects, with strong cash flow and nearly full-year cash conversion target achieved. U.K. sales dropped 11%, impacting profits, while efficiency and strategy updates are prioritized for 2026.
Arjo AB Annual report: Q4 2025
Arjo AB has published its Q4 2025 annual report on January 30, 2026.
Arjo AB Quarterly report: Q4 2025
Arjo AB has published its Q4 2025 quarterly earnings report on January 30, 2026.
Arjo AB Slides: Q4 2025
Arjo AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on January 30, 2026.
Arjo AB Earnings Call Transcript: Q3 2025
Organic net sales grew 3.8% year-over-year, led by strong global sales and robust service business. Profitability improved with adjusted EBITDA up and cash conversion at 105%. Despite margin headwinds from tariffs and currency, a strong order book and cost efficiency support a positive outlook.
Arjo AB Quarterly report: Q3 2025
Arjo AB has published its Q3 2025 quarterly earnings report on October 22, 2025.
Arjo AB Slides: Q3 2025
Arjo AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 22, 2025.